Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy With Tirzepatide, Empagliflozin and Pioglitazone Versus Standard Therapy in Newly Diagnosed Type 2 Diabetes
NCT07635953Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide, empagliflozin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Diabetic remission rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07635953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635953.